このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Safety Shot 配当金

配当金基準チェック /06

Safety Shot配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	3.2%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$0.56
3年後の配当利回り予想	n/a

最近の配当金アップデート

更新なし

Recent updates

Is Safety Shot (NASDAQ:SHOT) Using Debt In A Risky Way?

Mar 05

Jupiter Wellness to get US patent for minoxidil use in hair loss disorder

Sep 28

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Sep 20

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jul 26

Jupiter Wellness says developing a new women’s sexual health product

Jul 06

Jupiter Wellness: Advancing CBD-Based Medical Therapeutics And Wellness Products

Nov 30

Jupiter Wellness concludes enrollment in eczema study with JW-100

Dec 22

Vinco Ventures divests WOS to Jupiter Wellness

Dec 03

決済の安定と成長

配当データの取得

安定した配当: SHOTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: SHOTの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Safety Shot 配当利回り対市場

SHOT 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (SHOT)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.8%
業界平均 (Personal Products)	3.2%
3年後のアナリスト予想 (SHOT)	n/a

注目すべき配当: SHOTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: SHOTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: SHOTの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: SHOTが配当金を報告していないため、配当金の持続可能性を計算できません。

Safety Shot 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Safety Shot, Inc., Annual General Meeting, Jul 31, 2024

Safety Shot, Inc. Launch of Revolutionary Formula in New, Convenient 4-Ounce Bottles

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.051 loss in 1Q 2023)

Safety Shot, Inc. has filed a Follow-on Equity Offering in the amount of $4.999999 million.

New major risk - Revenue size

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.70 loss in FY 2022)

Safety Shot, Inc. Appoints David J. Long to the Board of Directors

Safety Shot, Inc Appoints Jordan Schur as President and Company Board Member

Is Safety Shot (NASDAQ:SHOT) Using Debt In A Risky Way?

New minor risk - Market cap size

Safety Shot, Inc. Announces Chief Executive Officer Changes

Safety Shot, Inc. Appoints Danielle De Rosa as Chief Financial Officer, Effective March 1,2024

Less than half of directors are independent

Safety Shot Appoints Rich Pascucci to Its Board of Directors

Safety Shot, Inc. Announces West Coast Launch of Safety Shot

Safety Shot, Inc. announced delayed 10-Q filing

New major risk - Shareholder dilution

Safety Shot, Inc., Annual General Meeting, Dec 05, 2023

Safety Shot Inc. Announces Direct-To-Consumer Launch of Safety Shot

Safety Shot, Inc. Appoints Jarrett Boon to its Board of Directors

The Honorable Jack Brewer, M.Ed. Joins Safety Shot’s Advisory Board

Jupiter Wellness Appoints Jarrett Boon as COO

Jupiter Wellness Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jupiter Wellness, Inc. Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: US$0.013 loss per share (vs US$0.066 loss in 2Q 2022)

Jupiter Wellness, Inc. Appoints David Long to its Advisory Board

Jupiter Wellness, Inc Announces Board Appointments

Jupiter Wellness, Inc. Announces Executive Changes

New major risk - Share price stability

Jupiter Wellness, Inc. (NasdaqCM:JUPW) agreed to acquire Assets of GBB Drink Lab Inc.

First quarter 2023 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2022)

Full year 2022 earnings released: US$0.69 loss per share (vs US$1.69 loss in FY 2021)

Jupiter Wellness, Inc. Appoints Hector Alila as Additional Director

Jupiter Wellness, Inc., Annual General Meeting, Dec 22, 2022

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.24 loss in 3Q 2021)

Less than half of directors are independent

Jupiter Wellness, Inc. Re-Opens Enrollment in Clinical Trial Comparison of JW-100 and EUCRISA for the Treatment of Eczema

Director recently bought US$105k worth of stock

Jupiter Wellness, Inc. Initiates Clinical Trial for Potential New Treatment for Tinnitus

Jupiter Wellness to get US patent for minoxidil use in hair loss disorder

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Jupiter Wellness, Inc. Announces Board Changes, Effective September 15, 2022

Second quarter 2022 earnings released: US$0.066 loss per share (vs US$0.36 loss in 2Q 2021)

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jupiter Wellness says developing a new women’s sexual health product

Jupiter Wellness Receives Non-Compliance Notice from Nasdaq Related to Listing Rule 5635(c)

Jupiter Wellness Receives Non-Compliance Letter from Nasdaq

Jupiter Wellness, Inc. Appoints Prof. Andy Goren, MD as Chief Medical Officer

Jupiter Wellness, Inc. (NasdaqCM:JUPW) acquired Assets from Applied Biology, Inc. on June 21, 2022.

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: US$1.69 loss per share (vs US$0.86 loss in FY 2020)

Jupiter Wellness, Inc. Announces Resignation of Ryan Allison as Chief Operating Officer

Less than half of directors are independent

Jupiter Wellness, Inc. Announces Executive Changes

Jupiter Wellness Communicates Nasdaq About Issue of Inadvertent Non-Compliance with Nasdaq Listing Rule 5635(C)

Jupiter Wellness, Inc. (NasdaqCM:JUPW) announces an Equity Buyback for $5 million worth of its shares.

Jupiter Wellness, Inc. (NasdaqCM:JUPW) signed a definitive agreement to acquire Next Frontier Brands.

Jupiter Wellness: Advancing CBD-Based Medical Therapeutics And Wellness Products

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.088 loss in 3Q 2020)

CEO & Executive Director recently bought US$73k worth of stock

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.062 loss in 2Q 2020)

Jupiter Wellness, Inc. Announces Inititation of Head-to-Head Trial Comparing JW-100 and Eucrisa® for the Treatment of Mild-to-Moderate Eczema

Jupiter Wellness, Inc. announced delayed annual 10-K filing

Jupiter Wellness, Inc. Announces Results of Clinical Study to Investigate the Safety and Efficacy of JW-100 its Proprietary Lotion Formulation for the Treatment of Atopic Dermatitis

New 90-day high: US$6.97

Jupiter Wellness Inc Appoints Ryan T. Allison as VP of Business Development

Jupiter Wellness, Inc. Appoints Nancy Torres Kaufman as A Director and Member of the Board's Audit Committee

Jupiter Wellness Completes Patient Enrollment in Clinical Study of Novel Cannabidiol Lotion JW-100 for the Treatment of Eczema

Jupiter Wellness concludes enrollment in eczema study with JW-100

Jupiter Wellness, Inc. (NasdaqCM:JUPW) acquired S.R.M. Entertainment Limited from Vinco Ventures, Inc. (NasdaqCM:BBIG) for $ 0.9 million.

Vinco Ventures divests WOS to Jupiter Wellness

Jupiter Wellness, Inc. Initiates an Exploratory Clinical Study in the Treatment of Herpes Labialis (Cold Sores) for Its Prescription Topical Cream Candidate JW-100

配当金基準チェック /06